All Trials

An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with HR+/HER2- unresectable locally advanced or metastatic breast cancer with measurable disease and progression after prior CDK4/6 inhibitor plus endocrine therapy are randomized to patritumab deruxtecan (HER3-targeted topoisomerase I antibody-drug conjugate) versus physician’s choice chemotherapy (paclitaxel, nab-paclitaxel, capecitabine, liposomal doxorubicin) or trastuzumab deruxtecan. Key exclusions include candidates for further endocrine therapy or PARP inhibitor (gBRCA+), visceral crisis, prior chemo for advanced disease, prior anti-HER3 or topo I ADCs, and active ILD/pneumonitis.

ClinicalTrials.gov ID: NCT07060807

Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic colorectal adenocarcinoma, grouped into three cohorts: dMMR/MSI-H refractory to prior PD-1/PD-L1 ± CTLA-4, pMMR/MSS with active non-bulky liver metastases, or pMMR/MSS without liver metastases (cohorts 2–3 post–fluoropyrimidine/oxaliplatin/irinotecan), receive ivonescimab monotherapy. Ivonescimab is a bispecific antibody targeting PD-1 and VEGF to relieve immune suppression and inhibit angiogenesis; primary endpoint is ORR by iRECIST.

ClinicalTrials.gov ID: NCT06959550

A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable pleural mesothelioma (epithelioid or non-epithelioid), ECOG 0–1, are randomized to volrustomig (a bispecific PD-1/CTLA-4 antibody) plus carboplatin/pemetrexed versus investigator’s choice of platinum/pemetrexed (epithelioid) or nivolumab plus ipilimumab (either histology; standard for non-epithelioid). Key exclusions include significant autoimmune disease and uncontrolled infections; primary endpoint is overall survival.

ClinicalTrials.gov ID: NCT06097728

A Single-Arm, Open-label Phase II Trial Testing the Activity of XL092 (Zanzalintinib) in Patients With Advanced Leiomyosarcoma

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic or unresectable leiomyosarcoma after at least two prior systemic regimens (≤2 prior TKIs), ECOG 0–1, receive oral zanzalintinib (XL092), a multi-kinase inhibitor of VEGFR2, MET, and TAM (TYRO3/AXL/MER), given continuously in 14‑day cycles until progression/toxicity. Key exclusions include prior XL092, significant cardiovascular/bleeding risk, unstable CNS disease, and concurrent oral anticoagulants.

ClinicalTrials.gov ID: NCT06571734

ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects With Leiomyosarcoma (ARGSARC): A Randomized, Double Blind, Multi-Center Phase 3 Trial

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced or metastatic grade 2–3 leiomyosarcoma (uterine or non‑uterine) after 1–2 prior systemic regimens including doxorubicin, ECOG 0–1, receive gemcitabine/docetaxel plus either ADI‑PEG 20 or placebo. ADI‑PEG 20 (pegargiminase) is a pegylated arginine deiminase that depletes extracellular arginine to target ASS1‑deficient, arginine‑auxotrophic tumors.

ClinicalTrials.gov ID: NCT05712694

A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic castration-resistant prostate adenocarcinoma, asymptomatic/mildly symptomatic, after exactly one prior ARPI (no small cell/neuroendocrine features; excluding brain or liver metastases), are randomized to BMS-986365 (gridegalutamide), an oral cereblon-recruiting androgen receptor degrader/antagonist, versus investigator’s choice of docetaxel/prednisone or a second ARPI (abiraterone/prednisone or enzalutamide). Primary endpoint is radiographic PFS with blinded central review.

ClinicalTrials.gov ID: NCT06764485

A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic castration-resistant prostate cancer progressing after ADT and 1–2 prior AR pathway inhibitors (no prior taxane for mCRPC) are randomized to ifinatamab deruxtecan (I-DXd), a B7-H3–targeted antibody–drug conjugate delivering a topoisomerase I inhibitor, versus docetaxel plus prednisone. Key exclusions include prior steroid-requiring ILD/pneumonitis and significant cardiovascular disease; primary endpoints are OS and rPFS.

ClinicalTrials.gov ID: NCT06925737

A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with mCRPC who have progressed on at least one AR-directed therapy and received exactly one prior taxane in the mCRPC setting (ECOG 0–1) are randomized to xaluritamig, a STEAP1×CD3 bispecific T‑cell engager, versus investigator’s choice of cabazitaxel or a second AR-directed therapy (abiraterone or enzalutamide). Suitable for patients with measurable or bone disease and no prior STEAP1‑targeted therapy; primary endpoint is overall survival.

ClinicalTrials.gov ID: NCT06691984

A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Men with metastatic castration-resistant prostate cancer who progressed on abiraterone (no prior ARSI, limited prior chemo) are randomized to mervometostat (PF-06821497), an EZH2 inhibitor, plus enzalutamide versus physician’s choice of enzalutamide or docetaxel. Intended for ECOG 0–2, castration-resistant patients without small cell features or active CNS disease.

ClinicalTrials.gov ID: NCT06551324

PREcision DIagnostics in Prostate Cancer Treatment (PREDICT)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with progressive mCRPC after ≥1 ARSI (and usually prior taxane) are assigned to treatment by tumor genomics: valemetostat (dual EZH1/EZH2 inhibitor) for select epigenetic targets, carboplatin plus cabazitaxel for aggressive/neuroendocrine features, or physician-choice therapy (cabazitaxel, abiraterone/prednisone, enzalutamide, or Lu-177-PSMA for PSMA-positive disease). Includes variant histologies, allows re-registration at progression, and requires adequate organ function with standard imaging per PCWG3/RECIST.

ClinicalTrials.gov ID: NCT06632977